Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
复制标题
DOI：
10.3390/ijms18040752
复制
发表时间：
2017-04-02
影响因子：
5.6
通讯作者：
Baba H
中科院分区：
文献类型：
--
作者：
Miyamoto Y;Suyama K;Baba H
转移性结直肠癌（mCRC）患者的结局已通过抗表皮生长因子受体（抗EGFR）抗体治疗得到改善，特别是当与预测性生物标志物联合使用以选择缺乏RAS突变的患者时。液体活检和下一代测序等新技术揭示了抗EGFR治疗耐药的潜在机制通过KRAS和EGFR胞外域的获得性突变发挥作用。参与下游EGFR信号传导的交叉作用分子效应物的突变也是抗EGFR治疗的阴性预测因子。在目前的综述中，我们描述了抗EGFR治疗的最新进展，并讨论了针对mCRC下游RAS-MAPK信号转导的新治疗策略。
Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly when combined with predictive biomarkers to select patients lacking RAS mutations. New technologies such as liquid biopsy and next-generation sequencing have revealed that potential mechanisms of resistance to anti-EGFR therapies act through acquired mutations of KRAS and the EGFR ectodomain. Mutations in cross-talking molecular effectors that participate in downstream EGFR signaling are also negative predictors for anti-EGFR therapy. In the current review, we describe recent advances in anti-EGFR therapy and discuss new treatment strategies to target downstream RAS-MAPK signaling in mCRC.